about
Inclusion complex of ITH12674 with 2-hydroxypropyl-β-cyclodextrin: Preparation, physical characterization and pharmacological effect.Nrf2-ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases.ITH14001, a CGP37157-Nimodipine Hybrid Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts Neuroprotection in Cerebral Ischemia.Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer's Disease.Neuroprotective mechanism of the novel melatonin derivative Neu-P11 in brain ischemia related models.New melatonin-cinnamate hybrids as multi-target drugs for neurodegenerative diseases: Nrf2-induction, antioxidant effect and neuroprotection.Sensory Input-Dependent Changes in Glutamatergic Neurotransmission- Related Genes and Proteins in the Adult Rat Trigeminal Ganglion.The microglial α7-acetylcholine nicotinic receptor is a key element in promoting neuroprotection by inducing heme oxygenase-1 via nuclear factor erythroid-2-related factor 2.Novel sulfoglycolipid IG20 causes neuroprotection by activating the phase II antioxidant response in rat hippocampal slices.ConBr, A Lectin Purified from the Seeds of Canavalia brasiliensis, Protects Against Ischemia in Organotypic Culture of Rat Hippocampus: Potential Implication of Voltage-Gated Calcium Channels.Small synthetic hyaluronan disaccharides afford neuroprotection in brain ischemia-related models.Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures.Addition to "ITH14001, a CGP37157-Nimodipine Hybrid Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts Neuroprotection in Cerebral Ischemia".Heme-Oxygenase I and PCG-1α Regulate Mitochondrial Biogenesis via Microglial Activation of Alpha7 Nicotinic Acetylcholine Receptors Using PNU282987.The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators.
P50
Q31149743-C123F270-8A41-4EFC-BC22-FE943CA23EA5Q38652602-10F9C451-C662-4CBB-B0F4-73BB75D5FD78Q38741583-EF3EBBDB-F889-4456-A3E0-6C0C50C93BFCQ38815295-4350A1F2-C9D8-4FB1-BE65-3107C802763DQ38851642-7C884EB0-7FCC-4632-BB45-D88533439C86Q38950400-02856F06-1003-40C4-A9A9-17664BAD41CBQ42126283-ED03CBC0-0618-4BFB-B9AE-FB09EC81F338Q42964845-C39C4D46-FA54-4396-81CF-EE3A9A6989D7Q46441431-733068AB-95E7-4282-B67B-83A4D8027FF6Q46477382-B1B67C3E-C15E-4405-B5D2-57AC0398C1FBQ46937770-8D56AB25-08DB-417F-BEB6-419E0EC1030FQ48125798-19A94910-81D4-4AE1-B037-9CFF12616A2BQ48344896-01494CA8-74A5-4C8B-A35C-81572F029483Q48555635-C917749F-7F2B-4719-916E-552F0418D5D6Q48950857-C674FCE7-E7C6-4A45-A186-249ADC2DBB0E
P50
description
investigador
@es
researcher
@en
name
Izaskun Buendia
@en
type
label
Izaskun Buendia
@en
prefLabel
Izaskun Buendia
@en
P108
P31
P496
0000-0002-4006-547X